Skip to main content
Premium Trial:

Request an Annual Quote

DNA Script Awarded $5.5M in Grant Funding

NEW YORK (GenomeWeb) – DNA Script announced today that it has been awarded $5.5 million in grant funding from the European Commission and French investment bank Bpifrance.

DNA Script manufactures synthetic DNA and RNA using a proprietary enzymatic technology and nucleotide chemistry. Earlier this year, it acquired an exclusive license to a novel DNA building block for use in enzymatic DNA synthesis from Dynamic Combinatorial Chemistry.

According to Paris-based DNA Script, the grant money will be provided in the form of subsidies and refundable advances through the EC's Horizon 2020 European Innovation Council program and Bpifrance's innovation development programs.

"We are excited about recent breakthroughs we have made with our technology platform, and these additional resources will allow us to further accelerate the development of the company," DNA Script Cofounder and CEO Thomas Ybert said in a statement.

The grants follow a Series A financing round led by Illumina Ventures, in which DNA Script raised €11 million ($13.5 million). It said it has raised a total of $24 million to date.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.